Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfonated albumin
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
Sulfonated albumin is a posttranslationally modified form of albumin that plays a significant role in the progression of nonalcoholic fatty liver disease (NAFLD)-related liver fibrosis. Elevated levels of sulfonated albumin are observed in both human and mouse models of NAFLD. It promotes inflammation, hepatic steatosis, and liver fibrosis by activating hepatic stellate cells (HSCs) through interaction with the GAL3 receptor, which subsequently triggers the endoplasmic reticulum (ER) stress pathway. Sulfonated albumin is being investigated as a potential diagnostic biomarker for liver fibrosis and an important therapeutic target for NAFLD.
02
Targets
GALR3 (Galanin receptor 3)
Beyond the preview
Go deeper on sulfonated albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfonated albumin.